Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Sofía Bruni"'
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Breast cancer is the most frequently diagnosed cancer and the principal cause of mortality by malignancy in women and represents a main problem for public health worldwide. Tumor necrosis factor α (TNFα) is a pro-inflammatory cytokine whose express
Externí odkaz:
https://doaj.org/article/665ab46c81af42b58517ab1b09a7e6d3
Autor:
Mara De Martino, Mercedes Tkach, Sofía Bruni, Darío Rocha, María F. Mercogliano, Mauro E. Cenciarini, María F. Chervo, Cecilia J. Proietti, Florent Dingli, Damarys Loew, Elmer A. Fernández, Patricia V. Elizalde, Eliane Piaggio, Roxana Schillaci
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Stat3 is constitutively activated in several tumor types and plays an essential role in maintaining their malignant phenotype and immunosupression. To take advantage of the promising antitumor activity of Stat3 targeting, it is vital to understand th
Externí odkaz:
https://doaj.org/article/304761e6292046bdad547449605fff86
Publikováno v:
Cancers. 15:1987
Breast cancer is the most common cancer in women and the leading cause of death. HER2 overexpression is found in approximately 20% of breast cancers and is associated with a poor prognosis and a shorter overall survival. Tratuzumab, a monoclonal anti
Autor:
Sofía Bruni, Gloria Inurrigarro, María F. Mercogliano, Cecilia J. Proietti, Isabel Frahm, Roxana Schillaci, M De Martino, Patricia V. Elizalde
Publikováno v:
Cancer Research. 79:P6-20
Background: Novel strategies aimed to overcome trastuzumab (Tz) resistance of HER2+ breast cancer (BC) are needed. Recently, we demonstrated a novel immune evasion strategy used by BC where tumor necrosis factor alpha (TNF) induces upregulation of th
Autor:
María Florencia Mercogliano, Roxana Schillaci, Sofía Bruni, Patricia V. Elizalde, Florencia L. Mauro
Publikováno v:
Cancers, Vol 13, Iss 564, p 564 (2021)
Cancers
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Cancers
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Tumor necrosis factor alpha (TNFα) is a pleiotropic cytokine known to have contradictory roles in oncoimmunology. Indeed, TNFα has a central role in the onset of the immune response, inducing both activation and the effector function of macrophages
Autor:
Anastasia Maria Zavitsanou, Sofía Bruni, Jennifer Cable, Dana Pe'er, Sumit K. Subudhi, Crystal L. Mackall, Catherine J. Wu, Matthew E. Griffin, Stefani Spranger, Jeffry A. Sosman, Catherine M. Bollard, Mikala Egeblad, Saso Cemerski, James P. Allison, Theresa Proia, Benjamin D. Greenbaum, Renier J. Brentjens, Elaine R. Mardis, Sangeeta Goswami, Garry P. Nolan
Publikováno v:
Annals of the New York Academy of SciencesReferences. 1489(1)
Cancer immunotherapy has dramatically changed the approach to cancer treatment. The aim of targeting the immune system to recognize and destroy cancer cells has afforded many patients the prospect of achieving deep, long-term remission and potential
Autor:
María F. Chervo, Darío Rocha, Mara De Martino, Roxana Schillaci, Damarys Loew, Patricia V. Elizalde, Eliane Piaggio, Elmer Andrés Fernández, Sofía Bruni, Cecilia J. Proietti, Florent Dingli, María Florencia Mercogliano, Mauro E. Cenciarini, Mercedes Tkach
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Oncoimmunology
CONICET Digital (CONICET)
Consejo Nacional de Investigaciones Científicas y Técnicas
instacron:CONICET
Oncoimmunology
Stat3 is constitutively activated in several tumor types and plays an essential role in maintaining their malignant phenotype and immunosupression. To take advantage of the promising antitumor activity of Stat3 targeting, it is vital to understand th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::862012d2b171a40d3aceae691ef5c9ab
https://www.tandfonline.com/doi/full/10.1080/2162402X.2020.1715767
https://www.tandfonline.com/doi/full/10.1080/2162402X.2020.1715767
Autor:
Santiago Madera, Franco Izzo, María F. Chervo, Agustina Dupont, Violeta A. Chiauzzi, Sofia Bruni, Ezequiel Petrillo, Sharon S. Merin, Mara De Martino, Diego Montero, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Agustina Roldán Deamicis, María F. Mercogliano, Cecilia J. Proietti, Roxana Schillaci, Patricia V. Elizalde, Rosalía I. Cordo Russo
Publikováno v:
Cell Death and Disease, Vol 14, Iss 12, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/f97153e8a240450a80194174d2482fd7
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/89813db880f840c8a0fc442bdcdfa259
Autor:
Roxana Schillaci, Sofía Bruni, María Florencia Mercogliano, Agustina Roldán Deamicis, Patricia V. Elizalde, Mara De Martino, Florencia L. Mauro
Publikováno v:
Cancer Research. 80:1913-1913
Lapatinib (LAP), a dual EGFR/HER2 tyrosine kinase inhibitor, is used as second-line therapy in women with HER2+ breast cancer (BC), but less than 25% of the patients achieve an objective response. An alternative therapeutic approach is needed to over